185 related articles for article (PubMed ID: 20962595)
1. Novel insights into the molecular origins and treatment of lung cancer.
Webb JD; Simon MC
Cell Cycle; 2010 Oct; 9(20):4098-105. PubMed ID: 20962595
[TBL] [Abstract][Full Text] [Related]
2. KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.
Guibert N; Ilie M; Long E; Hofman V; Bouhlel L; Brest P; Mograbi B; Marquette CH; Didier A; Mazieres J; Hofman P
Curr Mol Med; 2015; 15(5):418-32. PubMed ID: 25941815
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis].
Han C; Zou H; Ma J; Zhou Y; Zhao J
Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):882-91. PubMed ID: 20840818
[TBL] [Abstract][Full Text] [Related]
4. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
Rekhtman N; Brandt SM; Sigel CS; Friedlander MA; Riely GJ; Travis WD; Zakowski MF; Moreira AL
J Thorac Oncol; 2011 Mar; 6(3):451-8. PubMed ID: 21266922
[TBL] [Abstract][Full Text] [Related]
5. Integration of molecular profiling into the lung cancer clinic.
Pao W; Kris MG; Iafrate AJ; Ladanyi M; Jänne PA; Wistuba II; Miake-Lye R; Herbst RS; Carbone DP; Johnson BE; Lynch TJ
Clin Cancer Res; 2009 Sep; 15(17):5317-22. PubMed ID: 19706816
[TBL] [Abstract][Full Text] [Related]
6. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
Amann JM; Lee JW; Roder H; Brahmer J; Gonzalez A; Schiller JH; Carbone DP
J Thorac Oncol; 2010 Feb; 5(2):169-78. PubMed ID: 20035238
[TBL] [Abstract][Full Text] [Related]
7. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung.
Bernicker EH; Miller RA; Cagle PT
J Oncol Pract; 2017 Apr; 13(4):221-227. PubMed ID: 28399384
[TBL] [Abstract][Full Text] [Related]
9. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition.
Rouleau E; Spyratos F; Dieumegard B; Guinebretière JM; Lidereau R; Bièche I
Br J Cancer; 2008 Dec; 99(12):2100. PubMed ID: 19078954
[No Abstract] [Full Text] [Related]
11. Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.
Zhang J; Park D; Shin DM; Deng X
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):11-6. PubMed ID: 26578706
[TBL] [Abstract][Full Text] [Related]
12. Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer.
Hoque MO; Brait M; Rosenbaum E; Poeta ML; Pal P; Begum S; Dasgupta S; Carvalho AL; Ahrendt SA; Westra WH; Sidransky D
J Thorac Oncol; 2010 Dec; 5(12):1887-93. PubMed ID: 21102258
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
Renaud S; Falcoz PE; Schaëffer M; Guenot D; Romain B; Olland A; Reeb J; Santelmo N; Chenard MP; Legrain M; Voegeli AC; Beau-Faller M; Massard G
Br J Cancer; 2015 Oct; 113(8):1206-15. PubMed ID: 26372703
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
[TBL] [Abstract][Full Text] [Related]
15. Clinical testing for molecular targets for personalized treatment in lung cancer.
Lam DC
Respirology; 2013 Feb; 18(2):233-7. PubMed ID: 22957484
[TBL] [Abstract][Full Text] [Related]
16. Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.
Daga A; Ansari A; Patel S; Mirza S; Rawal R; Umrania V
Asian Pac J Cancer Prev; 2015; 16(10):4147-56. PubMed ID: 26028064
[TBL] [Abstract][Full Text] [Related]
17. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
Jackman DM; Miller VA; Cioffredi LA; Yeap BY; Jänne PA; Riely GJ; Ruiz MG; Giaccone G; Sequist LV; Johnson BE
Clin Cancer Res; 2009 Aug; 15(16):5267-73. PubMed ID: 19671843
[TBL] [Abstract][Full Text] [Related]
18. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
Zarredar H; Pashapour S; Ansarin K; Khalili M; Baghban R; Farajnia S
J Cell Physiol; 2019 Feb; 234(2):1560-1566. PubMed ID: 30132854
[TBL] [Abstract][Full Text] [Related]
20. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
